[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl-

Request For Quotation

[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- manufacturers

  • SOS1-IN-5
  • SOS1-IN-5 pictures
  • $2785.00
  • 2026-05-11
  • CAS:2716956-47-5
  • Purity:
  • Supply Ability: 10g
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Basic information
Product Name:[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl-
Synonyms:SOS1-IN-5;[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl-
CAS:2716956-47-5
MF:C26H31F3N4O5
MW:536.54
EINECS:
Product Categories:
Mol File:2716956-47-5.mol
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Structure
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Chemical Properties
Boiling point 614.9±55.0 °C(Predicted)
density 1.273±0.06 g/cm3(Predicted)
pka6.57±0.20(Predicted)
Safety Information
MSDS Information
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Usage And Synthesis
UsesSOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4)[1].
References[1] Xin Li, et al. Pyrimidobicyclic derivatives, their preparation method and their application in medicine. Patent WO2021203768A1.
[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl- Preparation Products And Raw materials
Tag:[1,4,7,10,13]Pentaoxacyclopentadecino[2,3-g]quinazolin-4-amine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7,8,10,11,13,14,16,17-octahydro-2-methyl-(2716956-47-5) Related Product Information
2,7-Diazaspiro[4.4]nonane-2-acetamide, α-cyclopentyl-7-[[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl]-N-[(1R,10S,12S,18S)-1-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-2,7,8,10,11,12,13,16,17,18,19,21,22,23-tetradecahydro-22,22-dimethyl-13,19-dioxo-2-(2,2,2-trifluoroethyl)-15H-3,5-etheno-14,18-imino-6,10-methano-6H-pyrrolo[3,4-g][1,12,4,18]dioxadiazacyclodocosin-12-yl]-, (αS,5S)- NAV2729 Y-27632 1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro- RMC6291 RMC-7977